Brentuximab vedotin
- BNF:
- 8.1.5
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
RED:
- NICE TA478: - for treating relapsed or refractory systemic anaplastic large cell lymphoma. (NHSE commissioned). (Decision date - November 2017).
- NICE TA524: for treating CD30-positive Hodgkin lymphoma. (Replaces NICE TA446). (NHSE commissioned). (Decision date - July 2018).
- NICE TA577: for treating CD30-positive cutaneous T-cell lymphoma. (NHSE commissioned). (Decision date - May 2019).
- NICE TA641: in combination for untreated systemic anaplastic large cell lymphoma. (NHSE commissioned). (Decision date - September 2020).
Do Not Prescribe (DNP):
- NICE TA594: untreated advanced Hodgkin lymphoma. (Terminated appraisal). (Decision date - September 2019).
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again